Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical Inc (RMTI) delivers innovative therapies for chronic kidney disease and hemodialysis patients, including the only FDA-approved iron replacement therapy administered via dialysate. This page provides investors and healthcare professionals with centralized access to official press releases, clinical trial updates, and business developments directly impacting renal care innovation.
Track RMTI's progress in advancing dialysis solutions like triferic® and critical concentrates that maintain metabolic balance during treatment. Stay informed about regulatory milestones, partnership announcements, and research breakthroughs that shape the company's role in improving patient outcomes.
Key updates across three focus areas: iron deficiency management advancements, dialysis product innovations, and strategic initiatives enhancing renal care delivery. Bookmark this resource for verified information on RMTI's contributions to reducing treatment complications in ESRD patients.
Rockwell Medical has announced that its international partner, Drogsan Pharmaceuticals, received priority review status for the Marketing Authorization application and high priority status for the GMP application of Triferic AVNU from the Turkish Medicines and Medical Devices Agency. Triferic AVNU is an iron replacement therapy aimed at maintaining hemoglobin levels in adult hemodialysis patients. Rockwell entered license and supply agreements with Drogsan in June 2021, allowing Drogsan to exclusively commercialize Triferic products in Turkey. With steady progress towards regulatory approval anticipated in 2024, Rockwell Medical is optimistic about generating revenue through these international partnerships, enhancing its growth strategy in the hemodialysis market.
FAQ
What is the current stock price of Rockwell Med (RMTI)?
What is the market cap of Rockwell Med (RMTI)?
